Moderna's COVID-19 vaccine reported to be 94.5% effectiveNews


Bourla, when questioned about the "remarkable" timing of the announcement, told CNN that the company released it "when the science told us the data was available".

US biotech firm Moderna on Monday reported that its experimental vaccine is 94.5 percent effective in preventing COVID-19, based on its interim data from a late-stage clinical trial.

Pfizer reiterated that it expects to make as many as 50 million vaccine doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.

The data from Moderna's trial involving 30,000 volunteers also showed the vaccine prevented cases of severe COVID-19, a question that still remains with the Pfizer vaccine.

The analysis was conducted after 20 participants developed the virus and compared to how many had received the vaccine versus a placebo. Moderna and Johnson & Johnson have said they hope to start testing the vaccine in younger patients soon.

Pfizer shares were 2.6% higher in USA morning trade at $36.98 and US -listed shares of partner BioNTech SE were up 3% at $89.61. For that we wait for the data. The preliminary Pfizer and BioNTech trial result was based on 94 infected volunteers.

The distribution of a Pfizer shot is complicated by the need to store it at ultra-cold temperatures of -70 degrees Celsius. It can be stored for up to five days at standard refrigerator temperatures or for up to 15 days in a thermal shipping box.

"Don't get distracted: the news is not 95% protection, safety or effectiveness".

Moderna, part of the USA government's Operation Warp Speed program, expects to produce about 20 million doses for the United States this year, millions of which the company has already made and is ready to ship if it gets FDA authorization.

Meanwhile, reacting to the update, UK's medicines regulator said the final late-stage trial results from Pfizer and BioNTech's Covid-19 vaccine candidate were very encouraging, adding it would need to see the full data before making an assessment of the shot. It said only a small percentage of those who received the vaccine experienced mild side effects, such as body aches and headaches.

Pfizer said the efficacy of the vaccine was consistent across different age and ethnic groups, a sign that the immunization could be employed broadly around the world.Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94 per cent.

"Generally, the results published so far show that there's a good antibody reaction, as well as a good cellular immune response". Three contracts of this type have already been signed by the European Union: with AstraZeneca, Johnson & Johnson (400 million doses each) and Sanofi-GSK (300 million). The Commission has also concluded "successful" exploratory talks with Moderna, it said in a statement released yesterday.

Pfizer said its two-dose vaccine, called BNT162b2, was well-tolerated and that side effects were mostly mild to moderate, and cleared up quickly.



Latest news

76ers trading Horford, picks to Thunder for Green, Ferguson
He averaged 8.0 points and 3.3 rebounds while shooting 36.7% from deep over 68 regular-season games with LA (all starts). The Thunder will enter the draft with four picks: No. 25, No. 28, No. 34 and No. 53.

Republican Majority Leader Gazelka Tests Positive for Virus
He says he is not experiencing any major issues or symptoms and he expects "like 99% of the people" he will make a full recovery. Minnesota's case positivity rate is above 10 percent, twice the level at which COVID-19 spread is considered controllable.

CHINA Chinese experimental vaccine induces a quick response
A good immune response was "consistent across age, gender, race and ethnicity demographics", Pfizer said. Researchers say the latest results for CoronaVac support moving forward to Phase 3 trials.

Australia 'will always be Australia,' PM responds to China grievances
Prime Minister Scott Morrison dismissed criticism that Australia acted at the behest of the U.S. in crafting foreign policy. The list of grievances from the Chinese embassy.

Vega flight VV17 SEOSAT-Ingenio / TARANIS mission failure
The launch failure, the second for Arianespace in its past three attempts, represents a loss of $US400 ($548) million, reports SpaceflightNow.

Other news